DTCFF

DEFENCE THERAPEUTICS A by DEFENCE THERAPEUTICS INC (DTCFF)

About DEFENCE THERAPEUTICS A by DEFENCE THERAPEUTICS INC (DTCFF)

Defence Therapeutics, Inc. engages in the research and development of anti-body drug conjugates. It focuses on enhancing intracellular delivery of biological or biosimilar therapeutic drugs targeting cancer and infectious diseases. The company was founded by Simon Beaudoin and Sébastien Plouffe on July 18, 2017 and is headquartered in Vancouver, Canada.

Details

Daily high

$0.60

Daily low

$0.56

Price at open

$0.58

52 Week High

$1.16

52 Week Low

$0.27

Market cap

32.6M

Dividend yield

0.00%

Volume

15,172

Avg. volume

61,689

P/E ratio

-11.76

DEFENCE THERAPEUTICS A by DEFENCE THERAPEUTICS INC News